Compare Charles River Laboratories Intl. Inc (CRL) vs Corsair Gaming Inc (CRSR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Corsair Gaming Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231.16 (market cap $11.14B), while Corsair Gaming Inc trades at $9.81 (market cap $1.03B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 10.8× Corsair Gaming Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.
| CRL | CRSR | |
|---|---|---|
Market Cap | $11.14B | $1.03B |
Sector | Health | Technology |
52-Week High | $233.60 | $12.14 |
52-Week Low | $145.57 | $4.58 |
Enterprise Value | $14.00B | $1.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
CRSR trades at $9.47, down 1.97% today, with a bullish technical signal from moving averages and a consensus analyst price target of $9.00. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q3 2025 missed. Revenue for 2025 was $1.47B with a net loss of $16.16M, but 2026 projects a net profit of $7M. Positive news includes AI product launches and partnerships, driving investor optimism amid a mixed analyst rating of 4 Buy and 7 Hold.
Outlook is cautiously optimistic with potential from AI expansion and earnings growth, but risks include thin profit margins and competitive pressures. The stock's current price near the consensus target suggests limited upside, requiring strong execution for further gains. Investors should weigh the bullish technicals against fundamental challenges in the gaming hardware sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →
